

Electronic Supplementary Information

Switchable ^{19}F MRI Polymer Theranostics: Towards In Situ Quantifiable Drug Release

A. V. Fuchs,^{a,b,c} A. P. Bapat,^b G. J. Cowin^b and K. J. Thurecht^{a,b,c}

^a Australian Institute of Bioengineering and Nanotechnology, University of Queensland, Brisbane, 4072, Australia.

^b Centre for Advanced Imaging, University of Queensland, Brisbane, 4072, Australia.

^c ARC Centre of Excellence in Convergent Bio-Nano Science and Technology.

E-mail: k.thurecht@uq.edu.au




Figure S1. ^1H NMR (500 MHz, DMSO-d_6) of DTX-ketone.




Figure S2. (a) ^1H (400 MHz) and (b) ^{13}C (101 MHz) NMR of 2-((2-hydroxyethyl)disulfanyl)ethyl methacrylate in CDCl_3 .




Figure S3. (a) ^1H (400 MHz) and (b) ^{13}C (101 MHz) NMR of CPT-SS-MA in CDCl_3 .




Figure S4. ^{19}F NMR (471 MHz, DMSO-d_6) spectra of HBP-CPT (top), HBP-DTX, HBP-DOX, HBP-deprotected and, HBP-protected (bottom).




Figure S5. ^{19}F T_2 decay curves at various time points of HBP-DTX in PBS pH 7 and 5 (471 MHz, 10% D_2O).